Lincoln Alternative Strategies LLC's 9.94% Ownership in Purple Biotech Ltd.

Lincoln Alternative Strategies LLC has filed a Schedule 13G with the SEC, disclosing a 9.94% ownership in Purple Biotech Ltd. The filing indicates that Lincoln Alternative Strategies LLC beneficially owns 605,000 American Depositary Shares (ADS), each representing 200 ordinary shares of Purple Biotech Ltd. The shares are held solely by Lincoln Alternative Strategies LLC, with no shared voting or dispositive power. The filing certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The filing is made under Rule 13d-1(c) and is signed by Stephen Temes, Managing Member of Lincoln Alternative Strategies LLC.